Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Lancaster, JM, Havrilesky, LJ, and Berchuck, A. "The Genetic Etiology of Sporadic Ovarian Cancer." (January 1, 2003): 139-155. (Chapter)

Full Text

Havrilesky, LJ, Alvarez, AA, Sayer, RA, Lancaster, JM, Soper, JT, Berchuck, A, Clarke-Pearson, DL, Rodriguez, GC, and Carney, ME. "Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer." Gynecologic oncology 88, no. 1 (January 2003): 51-57.

Full Text

Havrilesky, LJ, Alvarez, AA, Whitaker, RS, Marks, JR, and Berchuck, A. "Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations." Gynecologic oncology 83, no. 3 (December 2001): 491-500.

Full Text

van Haaften-Day, C, Shen, Y, Xu, F, Yu, Y, Berchuck, A, Havrilesky, LJ, de Bruijn, HW, van der Zee, AG, Bast, RC, and Hacker, NF. "OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal." Cancer 92, no. 11 (December 1, 2001): 2837-2844.

Scholars@Duke

Havrilesky, LJ, McMahon, CP, Lobenhofer, EK, Whitaker, R, Marks, JR, and Berchuck, A. "Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones." J Soc Gynecol Investig 8, no. 2 (March 2001): 104-113.

Scholars@Duke

Haaften-Day, CV, Shen, Y, Xu, F, Yu, Y, Berchuck, A, Havrilesky, LJ, Bruijn, HWAD, Zee, AGJVD, Jr, RCB, and Hacker, NF. "OVXL, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma a critical appraisal." Cancer 92, no. 11 (2001): 2837-2844.

Full Text

Havrilesky, LJ, Elbendary, A, Hurteau, JA, Whitaker, RS, Rodriguez, GC, and Berchuck, A. "Chemotherapy-induced apoptosis in epithelial ovarian cancers." Obstet Gynecol 85, no. 6 (June 1995): 1007-1010.

Scholars@Duke

Havrilesky, LJ, Hurteau, JA, Whitaker, RS, Elbendary, A, Wu, S, Rodriguez, GC, Bast, RC, and Berchuck, A. "Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta." Cancer Res 55, no. 4 (February 15, 1995): 944-948.

Scholars@Duke

Elbendary, A, Berchuck, A, Davis, P, Havrilesky, L, Bast, RC, Iglehart, JD, and Marks, JR. "Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells." Cell Growth Differ 5, no. 12 (December 1994): 1301-1307.

Scholars@Duke

Berchuck, A, Elbendary, A, Havrilesky, L, Rodriguez, GC, and Bast, RC. "Pathogenesis of ovarian cancers." J Soc Gynecol Investig 1, no. 3 (July 1994): 181-190.

Scholars@Duke

Pages